Omnitarg And Herceptin Could Save Women Without Chemotherapy From Breast Cancer – Part 2 of 3
The team will continue following the patients to see if remission at surgery affects their outcome. Another memorize showed the combination of Omnitarg and Herceptin, when given with the chemotherapy drug docetaxel, eradicated 46 percent of tumors, 50 percent more than the results achieved without Omnitarg. Also, 17 percent of tumors were eradicated by combining the two targeted drugs and skipping chemotherapy, the researchers said.
And “Our con is the only one that has tested the hypothesis that Omnitarg and Herceptin could work without chemotherapy in these women,” said govern researcher Dr Luca Gianni, director of medical oncology at the Fondazione IRCCS Istituto Nationale Tumori Fondazione IRCCS Istituto di Milano in Italy. The third study, which included 455 patients followed at 99 sites for nearly two years, indicated that a array of Tykerb, Herceptin and the chemotherapy drug Taxol improved tumor response rates significantly more than any of the drugs alone.
The hang out led to a 51 percent remission rate, compared to 29 percent for a single therapy, said lead researcher Dr Jose Baselga, chief of the segment of hematology and oncology and associate director of the Massachusetts General Hospital Cancer Center. “With these new therapies, we could easily go to curing over 90 percent of these patients, which is remarkable since this was the most lethal good of breast cancer 10 years ago. This is a very fast advancement of new therapies,” Untch agreed.